| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President and CEO
1 company
Jay R. Luly is President and CEO at ENTA. Jay R. Luly's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $9.0M at current prices.
Historically, Jay R. Luly's trades have earned a strong insider score of 71/100 across 7 rated trades. Over a 12-month horizon, 83.3% of those trades were profitable, with an average 12-month return of +29.3%.
The ENTA filings lean toward selling, a net 139,543 shares.
Jay R. Luly has 51 Form 4 filings on record from January 2015 to February 2026, all as President and CEO at Enanta Pharmaceuticals (ENTA), 2015–2026.
The 90 reported transactions were 23 open-market sales, 18 stock awards, 16 tax withholdings and 16 option or other derivative awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $256K and 11 sales worth about $11.9M.
The only open-market purchase was 45,000 shares of ENTA at an average $5.69 on February 12, 2025, about $256K. Twelve months later ENTA was up 136%.
The largest open-market sale was 35,000 shares of ENTA at an average $125.24 on July 6, 2018, about $4.4M.
1 of the 3 sales since April 2023 was made under a Rule 10b5-1 trading plan; the other 2 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 5, 2025 | ENTA Enanta Pharmaceuticals Inc | President and CEO | Sell | 4,743 | $14.23 | $67,492.89 | -0.5% | -5.8% | - | |
| Feb 12, 2025 | ENTA Enanta Pharmaceuticals Inc | President and CEO | Buy | 45,000 | $5.69 | $256,050.00 | +5.6% | -10.8% | +136.2% | |
| Dec 6, 2024 | ENTA Enanta Pharmaceuticals Inc | President and CEO | Sell10b5-1 | 5,142 | $8.06 | $41,444.52 | -0.6% | -10.3% | +82.5% | |
| Dec 5, 2023 | ENTA Enanta Pharmaceuticals Inc | President and CEO | Sell | 7,230 | $9.63 | $69,624.90 | -0.9% | +65.3% | -9.9% | |
| Mar 13, 2023 | ENTA Enanta Pharmaceuticals Inc | President and CEO | Sale+OE | 27,912 | $45.16 | $1,260,628.34 | -3.3% | -43.4% | -67.7% | |
| Dec 16, 2022 | ENTA Enanta Pharmaceuticals Inc | President and CEO | Sale+OE | 30,000 | $44.72 | $1,341,712.85 | -3.7% | -4.3% | -79.4% | |
| Sep 15, 2021 | ENTA Enanta Pharmaceuticals Inc | President and CEO | Sell | 4,516 | $59.06 | $266,697.80 | -0.7% | +18.5% | -1.2% | |
| Jul 6, 2018 | ENTA Enanta Pharmaceuticals Inc | President and CEO | Sell | 35,000 | $125.24 | $4,383,459.58 | -5.6% | - | - | |
| May 17, 2018 | ENTA Enanta Pharmaceuticals Inc | President and CEO | Sell | 25,000 | $105.83 | $2,645,654.89 | -3.8% | - | - | |
| Mar 9, 2015 | ENTA Enanta Pharmaceuticals Inc | President and CEO | Sell | 15,000 | $33.37 | $500,520.67 | -3.1% | - | - |